Palliative care

Palliative care is the effort to relieve a patient’s pain, anxiety, and suffering; in the Memorial investigation, it became a contested description of medication given during a disaster. The central distinction was not simply whether drugs were present, but whether they were used to comfort patients or with the purpose of accelerating death. Staff accounts, prescriptions, postmortem findings, and competing expert interpretations left that distinction at the center of both the ethical inquiry and the criminal case.

Comfort as the stated purpose

During interviews, Susan Mulderick said that the idea of giving some patients medication arose in a discussion with Anna Pou on Thursday morning. Mulderick recalled asking whether patients could receive something for what she considered their suffering, anxiety, and pain. Pou was unsure what to give, Mulderick said, so she offered to ask Ewing Cook to speak with her. Mulderick said she did not see medication administered and did not know whether Pou followed up.

Asked whether there had been discussion of euthanasia, Mulderick denied discussing the specific act of euthanizing patients. She also denied discussing palliative treatment that might ease pain while speeding the dying process. She described the purpose of her conversations as comforting patients, not hastening death. Her account therefore placed the request within a recognizable distinction: relief of distress as the intended end, rather than death as the intended end.

The investigation also complicated Mulderick’s explanation. She gave Ativan as an example of a drug that could relax patients, but prescriptions seized from the pharmacy showed that Ativan and other ordinary comfort medications had already been prescribed for patients by Pou and other doctors during the disaster. That record made the proposed need for Cook to explain such medications to Pou difficult for investigators to understand. It did not, by itself, establish what any particular dose was intended to do; it did make the claimed sequence of events a matter for scrutiny.

Medication and clinical context

The book distinguishes the purpose of palliative care from the mere presence of medication. Morphine and Midazolam appeared in the investigation because both were detected in patients’ remains, and because the drugs could suppress breathing. Their detection raised questions about exposure and possible effects, but it did not alone answer whether a patient had received appropriate comfort treatment, an excessive dose, or medication intended to cause death.

That distinction shaped the forensic work. Frank Minyard initially doubted that autopsies would be useful because the bodies had remained in heat for more than a week, making blood testing unavailable. A volunteer pathologist advised that drugs might remain detectable in more durable tissues or abdominal fluid. Investigators consequently sent tissue samples from eighteen Memorial Medical Center bodies to National Medical Services, Inc. In an early report on those cases, nine tested positive for Morphine and about five or six for Midazolam.

The subsequent interpretation remained uncertain. Robert Middleberg, the laboratory director, cautioned that postmortem tissue results were not as straightforward as blood tests from living patients: heat and decomposition could alter drug concentrations. The experts therefore reviewed medical histories alongside laboratory results, asking whether the drugs had been given in a single dose or repeatedly, whether kidney or liver disease could affect accumulation, and whether the combination could dangerously suppress breathing in a patient not on a respirator. The questions matter to the concept of palliative care because clinical purpose and clinical effect cannot be inferred from a drug name alone.

A patient-specific inquiry

The experts’ review of LifeCare patient Alice Hutzler illustrates how the investigation tested medication against an individual record. Hutzler, a ninety-year-old nursing-home resident being treated for pneumonia, had Morphine and Midazolam in her liver, brain, and muscle tissue. Her chart, which was current until a few hours before her death was recorded on September 1, contained no prescription for either drug. It also recorded no complaints of pain or distress on the preceding night that indicated a need for them.

Those details did not resolve every uncertainty about dose or cause of death, but they gave investigators a way to ask whether medication could be explained as a response to documented symptoms and treatment. The case-by-case approach resisted treating all detected drugs as equivalent evidence. It placed laboratory results alongside prescriptions, recorded condition, and the timing of care—evidence relevant to whether comfort was the clinical rationale, without making that rationale self-proving.

Ethical and legal boundaries

Arthur Caplan, a bioethicist asked by Minyard to review the records of nine LifeCare patients on the seventh floor, concluded that all had been euthanized and that the way the drugs were administered did not accord with prevailing United States ethical standards for palliative care. In Caplan’s account of those standards, a patient’s death cannot be the goal of a doctor’s treatment. His conclusion directly challenged any attempt to treat the label of comfort care as sufficient justification for medication when the intended outcome might instead have been death.

The case also turned on the doctrine of double effect: a treatment intended to relieve suffering may have a foreseeable harmful consequence, but that possibility differs ethically and legally from intending harm or death. Michael Morales, the prosecutor considering the case, found that distinction useful because Louisiana murder law required proof of specific criminal intent. The question he came to emphasize was whether the injections were intended to harm and kill or to palliate. Thus, palliative care entered the courtroom not merely as a medical category but as a way of examining intention.

Expert disagreement prevented the toxicology from supplying a simple answer. Steven Karch argued that drug levels in bodies kept in extreme heat for days could not reliably establish causes of death and advised that the medical causes remain undetermined. Michael Baden countered that uncertainty about the dose did not erase the finding that drugs were present shortly before death or, in his view, the absence of another competing cause. Cyril Wecht disputed Karch’s account of postmortem changes, reporting a small experiment that found no significant difference between drug levels in refrigerated samples and samples exposed to hot, humid conditions. The experiment was limited and unpublished, leaving it as one piece of contested evidence rather than a final resolution.

The concept’s role in the case

Palliative care supplied the investigation with a boundary to examine, not a conclusion that could settle the case by itself. The presence of medication could support a finding of exposure; clinical records could illuminate symptoms and prescriptions; toxicology could suggest possible effects. None of those categories alone necessarily established the purpose behind an administration. The dispute required investigators and prosecutors to keep these questions distinct while evaluating how they bore on one another.

That distinction became part of the case’s repeated deliberation. Michael Morales kept a glossary that included palliative care, euthanasia, double effect, agonal breathing, and triage; the Memorial matter proceeded through multiple charging conferences rather than the single conference usual in an ordinary case. Palliative care therefore stood at the crossing of bedside practice, disaster conditions, ethical standards, forensic uncertainty, and criminal intent. Its meaning in the book depends on the difference between relieving suffering and making death the treatment’s goal—a difference that the evidence made consequential, but difficult to prove.